|
Compound class:
Antibody
Comment: This recombinant fully human FXIIa-blocking antibody abolishes FXIIa enzymatic activity [2]. Inhibition of FXIIa by 3F7 offers a mechanism as a safe anticoagulant that prevents thrombosis without increasing therapy-associated bleeding [1]. Antibody 3F7 also mediates an anti-inflammatory effect (via the bradykinin-producing kallikrein-kinin system) that may be of clinical utility in acute edema disorders.
|
